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Open access under CC BY-NC-ND license.Ulcerative colitis (UC) is a disease of the mucosal layer, and
activity of the disease is assumed to be related to mucosal
appearance. Mucosal healing has emerged as a major
therapeutic goal in UC. Whether mucosal healing should be
the ultimate therapeutic goal in these patients is unknown.
Even when endoscopy suggests mucosal healing, evidence
of histologic activity has been observed. Histologic healing
requires complete recovery of the colonic mucosa, with
absence of inﬂammation or structural changes. Histologic
improvements have been linked with improved clinical
outcomes, such as a reduced risk of relapse and need for
surgery/hospitalization and a reduced risk of developing
cancer. Hence, there is a rationale for aiming for histologic
remission in UC. Numerous methods of classiﬁcation of
histologic activity in UC have been proposed, although only
some of these are widely used. We review the current
deﬁnitions of histologic remission, the range of scoring
systems most commonly used, and the evidence of histo-
logic improvement that is available from the latest thera-
pies for UC. We also highlight questions that will require
careful consideration if histologic remission is to become
more widely used as an end point in clinical trials and a
treatment goal in clinical practice.
Keywords: Inﬂammatory Bowel Disease; Histologic Assessment;
Disease Modiﬁcation.
In patients with ulcerative colitis (UC), mucosalhealing, routinely assessed by endoscopy, has
emerged as a major therapeutic goal because the
inﬂammation is limited to the mucosal layer.1 Mucosal
healing is not always an accurate indicator of histologic
healing because microscopic evidence of inﬂammation is
common even in patients with clinically and sigmoido-
scopically quiescent colitis.2 Several articles have evalu-
ated the importance of mucosal healing in UC; however,
they did not evaluate histologic healing.3–5
Historically, a poor correlation has been found be-
tween histologic ﬁndings and indices of activity for UC,
with abnormal histologic ﬁndings observed in a large
number of patients with UC in clinical and endoscopic
remission.2,6–9 Microscopic features of activity may
persist in macroscopically inactive disease, suggesting
that endoscopy may underestimate the extent of the
disease.7,10–13 A better correlation is found between
endoscopy and histology when the samples are obtainedduring active inﬂammation.14 Accumulating evidence
indicates that histologic healing may be associated with
better clinical outcomes in UC and could represent the
ultimate therapeutic goal in UC.7,15
Herein, we review current deﬁnitions of histologic
remission and healing, available histologic scores, the
impact of histologic remission on outcomes in UC, and
the efﬁcacy of UC-related medications in achieving his-
tologic remission.Deﬁning Histologic Remission
and Healing
Some clinical studies refer to “histologic remission” as
an end point,16–18 although many use the term “histo-
logic improvement,”19,20 often because the therapy un-
der investigation was not efﬁcacious enough to achieve
histologic remission and healing. In contrast, Korelitz7
and Gheorghe et al21 have used the term “histologic
healing.” Histologic healing has not been used in clinical
decision making, partly because histologic changes often
take longer to appear than clinical or endoscopic im-
provements,14,22 and partly because it has been ques-
tioned whether histologic remission is a realistic
treatment goal with currently available treatment op-
tions and whether it is practical to implement in daily
practice. D’Haens et al14 recommended that histologic
remission should not be used as a primary end point for
therapeutic efﬁcacy, but instead should be considered as
a secondary end point.
There seems to be confusion around the more
commonly used term “mucosal healing”, and whether
histologic healing forms a part of it. In 2007, the Inter-
national Organization for the Study of Inﬂammatory
Bowel Disease deﬁned mucosal healing as the absence of
friability, blood, erosions, and ulcers in all visualized
segments of the gut mucosa, excluding histologic healing
from this deﬁnition.14 By contrast, Lichtenstein and
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ceration, both microscopic and macroscopic, providing a
sigmoidoscopy score of 0, as assessed by the Ulcerative
Colitis Disease Activity Index. Other researchers used the
term “mucosal healing” to describe complete recovery of
the colonic mucosa, comprising both endoscopic and
histologic healing.21,24 In more recent clinical trials
assessing the efﬁcacy of biologics in UC, mucosal healing
was deﬁned by achieving a Mayo endoscopic subscore
of 0 or 1, excluding histologic healing.25 In contrast,
Korelitz7 argued that histologic healing should be a
minimal criterion for mucosal healing. Gheorghe et al21
deﬁned histologic healing as the absence of residual
mucosal inﬂammation with distinctive changes in crypt
architectural distortion and/or atrophy, or completely
normal mucosa.26Methods Used to Measure Histologic
Activity and Categorize Histologic
Remission
Histologic features of UC are well documented,
comprising mild, moderate, or severe inﬂammatory ac-
tivity that results in distortion of the architecture of the
mucosal lining of the colon (Supplementary Figures 1
and 2).27 A standard system for grading histologic ac-
tivity does not exist28 and numerous methods of classi-
ﬁcation of histologic activity have been proposed
(Table 1).2,8,10,12,14,29–31 None of these scores has been
validated. Validation is a prerequisite for using one of the
scores to standardize reporting and grading. These
scores are based on H&E readings. Whether this is the
optimal method will require further investigation
because other techniques, such as immune histochemis-
try for myeloperoxidase, may be more accurate.
Furthermore, it should be noted that various factors can
affect histologic features when evaluating histologic
healing. These include timing of the biopsy (ie, newly
diagnosed vs chronic disease), site of biopsy (eg, rectal
therapy may normalize rectal histology whereas more
proximal colon remains histologically active), and patchy
healing (resulting from the natural history of UC or
multiple medical therapies).Impact of Histologic Remission on
Clinical Outcomes in Ulcerative Colitis
Several studies have shown that histologic healing is
associated with favorable clinical outcomes and is a
negative predictor of relapse in patients with UC and of
colon cancer risk (Figure 1).2,15,24,29 The presence of
histologic healing may deﬁne a subset of patients with
UC in whom treatment can be withdrawn.21 An early
study found that 57.9% of patients with no signiﬁcant
histologic inﬂammation after a course of corticosteroids
were symptom-free over the course of 1 year, comparedwith 16.7% of patients with evidence of inﬂammation on
a rectal biopsy.24
Histologic healing may be a better predictor of time to
relapse than macroscopic appearance or clinical
criteria.15 In a study of 82 patients with UC in symp-
tomatic and sigmoidoscopic remission, an acute inﬂam-
matory cell inﬁltrate, the presence of crypt abscesses,
and mucin depletion were associated with increased risk
of relapse.2 Acute inﬂammatory indicators were associ-
ated with a 2- to 3-fold increased risk of colitis during
12 months of follow-up evaluation. Bitton et al32 did not
replicate the ﬁndings of Riley et al2; however, their
multivariate analysis of data in 74 patients with inactive
UC identiﬁed an association between basal plasmacytosis
(a dense inﬁltration of plasma cells extending into the
lower third of the lamina propria) and shorter time to
relapse. There are some indications that eosinophils may
predict relapse, but this has not been studied in any
depth. In a small, prospective study of 26 patients with
quiescent UC, increased numbers of neutrophils and
eosinophils in the lamina propria were more frequent in
relapsers than nonrelapsers. An increase in basal
lymphoid aggregates in relapsers was observed, similar
to the ﬁndings of Bitton et al,32 but did not reach sta-
tistical signiﬁcance.33 Most recently, in a retrospective
analysis of a cohort of 75 patients with UC, Bessissow
et al34 showed that despite normal endoscopy, histologic
investigation showed inﬂammatory activity (Geboes
score, 3.1) in 40% of patients, and basal plasmacytosis
in 21% of patients. Clinical relapse was observed in 20%
(n ¼ 15) of patients at 12 months. Using multivariate
analysis, the presence of basal plasmacytosis predicted
UC clinical relapse (odds ratio [OR], 5.13; 95% conﬁ-
dence interval [CI], 1.32–19.99; P ¼ .019) in these pa-
tients with complete mucosal healing.
Histologic predictors of medically refractory UC also
have been investigated. One study observed that
lymphoid follicles were predictive of medically refractory
UC in patients aged 38 years or younger, whereas severe
cryptitis was predictive in patients aged older than 38
years.35 Furthermore, preliminary data have suggested
that increased histologic inﬂammation is predictive of
increased risk of colectomy and hospitalization in pa-
tients with UC.23 Similarly, in a large cohort of UC pa-
tients in a colonoscopic surveillance program, higher
mean inﬂammation score was a signiﬁcant predictor of
colectomy.36 Further evidence from a small cohort study
of patients with UC has shown histologic remission to be
associated with a lower rate of hospitalization (OR, 0.27;
95% CI, 0.07–0.95; P ¼ .048).15,37
Histologic remission also correlates with a reduction
in colorectal cancer risk. An epidemiologic case-control
study of 68 UC patients and 136 controls observed an
association between histologic inﬂammation score
and the risk of colorectal cancer by both univariate
and multivariate analyses (OR, 4.69; 95% CI, 2.10–10.47;
P < .001).38 Similarly, a cohort study of 418 patients
determined that the severity of histologic inﬂammation
Table 1.Methods Used to Classify and Score Histologic Activity in UC
Study Description Key features Comments
Truelove and
Richards8
Three categories of inﬂammation No signiﬁcant inﬂammation, general architecture of
mucosa often disturbed
Mild to moderate inﬂammation, neutrophils and
eosinophils often present
Severe inﬂammation, heavy inﬁltration by neutrophils
and eosinophils, crypt abscesses, erosions
Histologic remission deﬁned as a score of 1
Developed in 1956
Depends on subjective judgments
Riley et al2 Six histologic features were assessed: each feature
was graded on a 4-point scale corresponding to
none, mild, moderate, or severe
Acute inﬂammatory cell inﬁltrate (polymorphonuclear
cells in the lamina propria)
Crypt abscesses
Mucin depletion
Surface epithelial integrity
Chronic inﬂammatory cell inﬁltrate (round cells in the
lamina propria)
Crypt architectural irregularities
A simple subjective grading system
Reproducible
Geboes et al12 Histologic assessment scale: a 6-grade classiﬁcation
system for inﬂammation, also including subgrades
Grade 1: structural (architectural) change
Grade 2: chronic inﬂammatory inﬁltrate
Grade 3: lamina propria neutrophils and eosinophils
Grade 4: neutrophils in epithelium
Grade 5: crypt destruction
Grade 6: erosion or ulceration
A reproducible grading system that can be replicated
in clinical trials and routine clinical practice
Higher scores indicate more severe histologic
inﬂammation
The combination of endoscopy and biopsy provides a
better indication of activity than endoscopy alone
Florén et al10 Tissue inﬂammatory response graded on a
scale of 1–5
Grade 1: normal mucosa
Grade 2: enhanced glands, slight inﬂammation
Grade 3: reduced mucin production in some glands,
intermediate inﬂammation
Grade 4: marked gland and mucosal atrophy, severe
inﬂammation
Grade 5: ulceration, fulminant inﬂammation
Histologic remission was deﬁned as grade 1
Specimens were examined by the same pathologist
Hanauer et al30 Microscopic and histologic improvement Four-point categoric scale:
0 ¼ normal colonic mucosa through to 3 ¼ high-
grade, active inﬂammatory bowel disease
Remission, grade 0 or 1 (clinically normal mucosa or
inactive UC), with a minimum of a 1-grade
decrease from baseline to ﬁnal visit
Histologic changes were identiﬁed by a central
reference pathologist
Hanauer et al31 Histopathology score: Histopathology Evaluation
Inﬂammation Grade
Biopsy specimens were histologically graded for
active inﬂammation, chronic inﬂammation, and
crypt distortion (the intensity of each was scored on
a numeric scale from normal to high/severe)
Similar to the Truelove and Richards8 scale
Total histopathology score was derived from the sum
of the 3 components
Gupta et al29 Histological Activity Index Degree of inﬂammation was scored as follows:
0 ¼ inactive or absent, no epithelial inﬁltration by
neutrophils; 1 ¼ mild, neutrophil inﬁltration of
<50% of sampled crypts and cross-sections;
2 ¼ moderate, neutrophil inﬁltration of 50% of
sampled crypts and cross-sections; 3 ¼ severe,
erosion, or ulceration
Relatively simple index developed and used routinely
at Mount Sinai
High levels of intra-observer and interobserver
agreement
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Figure 1. Impact of histo-
logic remission on clinical
outcomes.
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advanced colorectal neoplasia among patients with long-
standing UC.29 Together, these data suggest that histo-
logic remission and healing is valuable in predicting
which patients will experience a more favorable disease
course.Impact of Medications on Histologic
Remission in Ulcerative Colitis
A major limitation in assessing the impact of available
therapies on histologic remission is that such an end
point has not been well deﬁned in most studies of his-
tologic activity.14 Very few therapies for UC have re-
ported achieving histologic remission (Supplementary
Table 1).16–19,39–42
In a study comparing a topically acting glucocorti-
costeroid budesonide retention enema with a predniso-
lone disodium phosphate enema in patients with active
distal UC, both treatments signiﬁcantly improved histo-
logic score.40 In a Cochrane systematic review of the
efﬁcacy and safety of oral budesonide for induction of
remission in UC, 3 studies met the inclusion criteria.42
One study showed a signiﬁcant reduction from baseline
in the histologic score of inﬂammation with both bude-
sonide and prednisolone, including some patients who
achieved histologic remission. In another study
comparing budesonide with mesalamine, histologic
remission was achieved by 46.9% and 58.4% of patients,
respectively. The review concluded that although histo-
logic improvement with budesonide had been reported,
there was still a lack of evidence to recommend oral
budesonide for the induction of remission in active UC.42
In a large randomized study comparing mesalamine
enema and budesonide in active left-sided UC, the
mesalamine enema treatment resulted in a nonsigniﬁ-
cantly higher rate of histologic remission (48.6%) thanbudesonide (43.0%; P ¼ .145).18 In a study of orally
administered mesalamine granules in patients with
active UC, 35% of patients receiving a once-daily dose
and 41% receiving a 3 times/daily dose achieved histo-
logic remission.17 A further Cochrane review of 38
eligible studies showed that rectal mesalamine is supe-
rior to placebo in inducing symptomatic, endoscopic, and
histologic improvement and remission, with a pooled OR
of 7.69 for histologic improvement (6 trials; P < .00001)
and 6.28 for histologic remission (5 trials; P < .0001).16
An early study of inﬂiximab therapy in patients with
UC observed a signiﬁcant improvement from baseline in
mean histologic score in 8 patients (P < .001) but did not
report histologic remission.19 A subgroup analysis of the
Active Ulcerative Colitis Trial I on patients with biopsy
specimens showed that at weeks 8 and 30, 35% of
inﬂiximab-treated patients and 24% of placebo patients
showed structural change unaccompanied by inﬂamma-
tory changes (grade 0), which equals healing.39
Summary and Perspectives
Histologic healing and mucosal healing are not
currently well differentiated, and there appears to be
confusion between the 2 terms. Clinicians currently are
focusing on mucosal healing, rather than histologic
healing or histologic remission, as a therapeutic goal in
patients with UC. Mucosal healing is associated with
better clinical outcomes in patients with UC; however,
histologic parameters may provide a more accurate pic-
ture of the recovery of the mucosa and further improve
disease outcomes. Available data indicate that histologic
healing may be associated with better outcomes in UC,
including lower relapse rates and cancer risk, providing a
rationale for making this a treatment goal.
The ﬁrst step is to better deﬁne histologic remission
and healing in UC. This will require an effort at the in-
ternational level. Indeed, there is a lack of uniformity
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well as a lack of deﬁned criteria for measuring histologic
activity and categorizing remission.
Histologic healing has been shown with currently
available therapies such as mesalamine, whereas data
from biologics are scarce. Histologic remission and
healing now are being incorporated as end points in UC
trials (www.clinicaltrials.gov/), which will allow corre-
lations with other disease measures and clinical out-
comes to be made.
Whether the current therapeutic armamentarium,
particularly antitumor necrosis factor therapy, proves to be
disease-modifying in UC in the long term remains to be
seen.43 With the arrival of newer treatment modalities for
UC, it is warranted to explore raising the bar in the treat-
ment of UC and further elucidate and deﬁne the potential
role of histologic remission for disease modiﬁcation.
Before considering changes to clinical practice, large
prospective studies addressing a number of key issues
are eagerly awaited. For example, “Should we optimize
therapies to achieve histologic healing to change the
course of UC?” and, “What is the degree of histologic
healing that is required to change the course of UC?”
Finally, the practicalities of implementing histologic
remission as a treatment goal in clinical practice need to
be considered. Histologic healing assessment requires
multiple and repeated biopsies, involving invasive pro-
cedures with associated costs, together with issues of the
time needed to complete the histologic analysis.
Recently, confocal laser endomicroscopy, which allows
microscopic evaluation of the mucosa during endoscopy
to identify histologic healing, has been proposed.21 This
will require further investigation.
Histologic remission and healing is an area of
increased research focus and holds the promise of being
an important marker of treatment efﬁcacy in UC, with the
potential to guide treatment decisions in the future.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
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1. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the
2nd Scientiﬁc Workshop of the ECCO. I: impact of mucosal
healing on the course of inﬂammatory bowel disease. J Crohns
Colitis 2011;5:477–483.
2. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in
ulcerative colitis: what does it mean? Gut 1991;32:174–178.
3. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing pre-
dicts late outcomes after the ﬁrst course of corticosteroids for
newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol
2011;9:483–489.e3.
4. Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the
ulcerative colitis colonoscopic index of severity and itscorrelation with disease activity measures. Clin Gastroenterol
Hepatol 2013;11:49–54.e1.
5. Turner D, Grifﬁths AM, Veerman G, et al. Endoscopic and clinical
variables that predict sustained remission in children with ul-
cerative colitis treated with inﬂiximab. Clin Gastroenterol Hep-
atol 2013;11:1460–1466.
6. Rosenberg L, Nanda KS, Zenlea T, et al. Histologic markers of
inﬂammation in patients with ulcerative colitis in clinical remis-
sion. Clin Gastroenterol Hepatol 2013;11:991–996.
7. Korelitz BI. Mucosal healing as an index of colitis activity: back
to histological healing for future indices. Inﬂamm Bowel Dis
2010;16:1628–1630.
8. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis.
Br Med J 1956;1:1315–1318.
9. Dick AP, Holt LP, Dalton ER. Persistence of mucosal abnor-
mality in ulcerative colitis. Gut 1966;7:355–360.
10. Florén CH, Benoni C, Willén R. Histologic and colonoscopic
assessment of disease extension in ulcerative colitis. Scand J
Gastroenterol 1987;22:459–462.
11. Gomes P, du Boulay C, Smith CL, et al. Relationship between
disease activity indices and colonoscopic ﬁndings in patients
with colonic inﬂammatory bowel disease. Gut 1986;27:92–95.
12. Geboes K, Riddell R, Öst A, et al. A reproducible grading scale
for histological assessment of inﬂammation in ulcerative colitis.
Gut 2000;47:404–409.
13. Lemmens B, Arijs I, Van Assche G, et al. Correlation between the
endoscopic and histologic score in assessing the activity of
ulcerative colitis. Inﬂamm Bowel Dis 2013;19:1194–1201.
14. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity
indices and efﬁcacy end points for clinical trials of medical
therapy in adults with ulcerative colitis. Gastroenterology 2007;
132:763–786.
15. Travis SPL, Higgins PDR, Orchard T, et al. Review article:
deﬁning remission in ulcerative colitis. Aliment Pharmacol Ther
2011;34:113–124.
16. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-amino-
salicylic acid for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev 2010:CD004115.
17. Kruis W, Kiudelis G, Rácz I, et al. Once daily versus three times
daily mesalazine granules in active ulcerative colitis: a double-
blind, double-dummy, randomised, non-inferiority trial. Gut
2009;58:233–240.
18. Hartmann F, Stein JBudeMesa-Study Group. Clinical trial:
controlled, open, randomized multicentre study comparing the
effects of treatment on quality of life, safety and efﬁcacy of
budesonide or mesalazine enemas in active left-sided ulcerative
colitis. Aliment Pharmacol Ther 2010;32:368–376.
19. Chey WY. Inﬂiximab for patients with refractory ulcerative colitis.
Inﬂamm Bowel Dis 2001;7(Suppl 1):S30–S33.
20. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor
alpha blocking agents for induction of remission in ulcerative
colitis. Cochrane Database Syst Rev 2006:CD005112.
21. Gheorghe C, Cotruta B, Iacob R, et al. Endomicroscopy for
assessing mucosal healing in patients with ulcerative colitis.
J Gastrointest Liver Dis 2011;20:423–426.
22. Geboes K, Dalle I. Inﬂuence of treatment on morphological
features of mucosal inﬂammation. Gut 2002;50(Suppl 3):iii37–iii42.
23. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in
ulcerative colitis. Inﬂamm Bowel Dis 2010;16:338–346.
24. Isaacs KL. How rapidly should remission be achieved? Dig Dis
2010;28:548–555.
934 Peyrin–Biroulet et al Clinical Gastroenterology and Hepatology Vol. 12, No. 625. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal
healing with inﬂiximab is associated with improved long-term
clinical outcomes in ulcerative colitis. Gastroenterology 2011;
141:1194–1201.
26. Levine TS, Tzardi M, Mitchell S, et al. Diagnostic difﬁculty arising
from rectal recovery in ulcerative colitis. J Clin Pathol 1996;
49:319–323.
27. Gramlich T, Petras RE. Pathology of inﬂammatory bowel dis-
ease. Semin Pediatr Surg 2007;16:154–163.
28. Cooney RM, Warren BF, Altman DG, et al. Outcome measure-
ment in clinical trials for ulcerative colitis: towards stand-
ardisation. Trials 2007;8:17.
29. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inﬂammation is
a risk factor for progression to colorectal neoplasia in ulcerative
colitis: a cohort study. Gastroenterology 2007;133:1099–1105.
30. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules
for treatmentof activeulcerative colitis: results of a controlled trial.
Pentasa Study Group. Am J Gastroenterol 1993;88:1188–1197.
31. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for
the treatment of active, distal ulcerative colitis and proctitis: a
dose-ranging study. U.S. Budesonide enema study group.
Gastroenterology 1998;115:525–532.
32. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological,
and histologic parameters as predictors of relapse in ulcerative
colitis. Gastroenterology 2001;120:13–20.
33. Azad S, Sood N, Sood A. Biological and histological parameters
as predictors of relapse in ulcerative colitis: a prospective study.
Saudi J Gastroenterol 2011;17:194–198.
34. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of
serologic and histologic markers on clinical relapse in ulcerative
colitis patients with mucosal healing. Am J Gastroenterol 2012;
107:1684–1692.
35. Melson JE, Giusto D, Kwasny M, et al. Histopathology pre-
dictors of medically refractory ulcerative colitis. Dis Colon
Rectum 2010;53:1280–1286.
36. Hefti MM, Chessin DB, Harpaz NH, et al. Severity of inﬂamma-
tion as a predictor of colectomy in patients with chronic ulcer-
ative colitis. Dis Colon Rectum 2009;52:193–197.37. Burger DC, Thomas SJ, Walsh AJ, et al. Depth of remission may
not predict outcome of UC over 2 years (abstr). J Crohns Colitis
2011;5:S4.
38. Rutter M, Saunders B, Wilkinson K, et al. Severity of inﬂam-
mation is a risk factor for colorectal neoplasia in ulcerative co-
litis. Gastroenterology 2004;126:451–459.
39. Geboes K, Rutgeerts P, Olson A, et al. Inﬂiximab results in
reduction of inﬂammation and inﬂammatory markers in the
mucosa of ulcerative colitis patients: the ACT 1 trial (abstr). Am J
Gastroenterol 2005;100:S287.
40. Löfberg R, Ostergaard Thomsen O, Langholz E, et al. Budeso-
nide versus prednisolone retention enemas in active distal ul-
cerative colitis. Aliment Pharmacol Ther 1994;8:623–629.
41. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or
methotrexate in the treatment of patients with steroid-dependent
or steroid-resistant ulcerative colitis: results of an open-label
study on efﬁcacy and tolerability in inducing and maintaining
remission. Aliment Pharmacol Ther 2002;16:1751–1759.
42. Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for
induction of remission in ulcerative colitis. Cochrane Database
Syst Rev 2010:CD007698.
43. Filippi J, Allen PB, Hebuterne X, et al. Does anti-TNF therapy
reduce the requirement for surgery in ulcerative colitis? A sys-
tematic review. Curr Drug Targets 2011;12:1440–1447.
Reprint requests
Address requests for reprints to: Laurent Peyrin–Biroulet, MD, PhD, Inserm,
U954 and Department of Hepato-Gastroenterology, University Hospital of
Nancy, Université Henri Poincaré 1, Vandoeuvre-lès-Nancy, France. e-mail:
peyrinbiroulet@gmail.com; fax: (33) 3-83-15-36-33.
Acknowledgments
The authors would like to thank Karen Brayshaw, PhD, at McCann Complete
Medical for her assistance in drafting the manuscript, (assistance funded by
Bristol-Myers Squibb).
Conﬂicts of interest
These authors disclose the following: Laurent Peyrin-Biroulet has received
consulting and/or lecture fees from Tillotts, Norgine, Shire, Ferring, Vifor,
Pharmacosmos, Mitsubishi, Genentech, Bristol-Myers Squibb, Merck, Jans-
sen, and Abbott; and Wendy Kampman is an employee of Bristol-Myers
Squibb. The remaining author discloses no conﬂicts.
Supplementary Figure 1. Histology of quiescent colitis. (A) Quiescent colitis with marked architectural changes in UC. (B)
Architectural changes are characterized by loss of crypt parallelism with branching crypts. (C) Distal Paneth cell metaplasia
can be present, indicating a long history of colitis (arrows).
Supplementary Figure 2. Histology of mildly and moderately active colitis. (A) Mildly active colitis with cryptitis lesion,
characterized by neutrophils that focally inﬁltrate the crypt (arrow). (B) Moderately active UC with crypt abscess formation
characterized by a collection of neutrophils in the crypt lumen (arrow). H&E staining: magniﬁcation, 200.
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Supplementary Table 1. Efﬁcacy of Current Medications in Improving Histologic Score in Patients With UC
Study Medication Effect on histologic score
Marshall et al16 Rectal mesalamine Superior to placebo in inducing histologic improvement (pooled OR, 7.69;
P < .00001) and histologic remission (pooled OR, 6.28; P < .0001)
Hartmann et al18 Mesalazine enema vs budesonide Nonsigniﬁcantly higher rate of histologic remission with mesalazine (48.6%)
vs budesonide (43.0%; P ¼ .145)
Kruis et al17 Orally administered mesalazine
granules
35% of patients receiving a once-daily dose and 41% receiving
a 3 times/d dose achieved histologic remission
Chey19 Inﬂiximab Signiﬁcant improvement from baseline in histologic score
(P < .001)
Geboes et al39 Inﬂiximab At weeks 8 and 30, 35% of inﬂiximab-treated patients and 24% of placebo
patients showed structural change unaccompanied by inﬂammatory changes
(grade 0) that equaled healing
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